Cargando…

An immunoradiometric assay of tumour-antigen 4 (TA-4): a comparison with conventional radioimmunoassay.

The serum level of tumour-antigen 4 (TA-4) was measured in 181 patients with squamous cell carcinoma (SCC) of various organs (71 lung, 24 uterus, 16 oesophagus, 64 head and neck and six skin), 34 patients with other types of lung cancer and 35 patients with benign diseases. To compare the results wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Mino-Miyagawa, N., Kimura, Y., Hamamoto, K.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1990
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971364/
https://www.ncbi.nlm.nih.gov/pubmed/2331438
_version_ 1782134894357381120
author Mino-Miyagawa, N.
Kimura, Y.
Hamamoto, K.
author_facet Mino-Miyagawa, N.
Kimura, Y.
Hamamoto, K.
author_sort Mino-Miyagawa, N.
collection PubMed
description The serum level of tumour-antigen 4 (TA-4) was measured in 181 patients with squamous cell carcinoma (SCC) of various organs (71 lung, 24 uterus, 16 oesophagus, 64 head and neck and six skin), 34 patients with other types of lung cancer and 35 patients with benign diseases. To compare the results with those obtained by the conventional competitive radioimmunoassay (RIA) using a polyclonal antibody, a new immunoradiometric assay (IRMA) method was used which has recently been developed using two monoclonal antibodies raised to different epitopes of TA-4. Both methods provided essentially the same results: the serum TA-4 levels were high in patients with SCC of various organs when compared with those of healthy controls and patients with other types of lung cancer or benign diseases. However, the positive ratios assessed as the percentage of patients with elevated serum TA-4 levels were higher with the IRMA method than with the RIA method in SCC of all organs, as much as 2-3 times higher in SCC of the larynx, tongue and pharynx. In contrast, in patients with benign diseases or other types of lung cancer, there was no difference in the positive ratios between the two methods. This was largely due to the improvement in sensitivity and accuracy of assay with the new method, which resulted in a decrease in the normal value in healthy controls. It was concluded that with the new IRMA method using monoclonal antibodies, the diagnostic detectability of serum TA-4 is enhanced in SCC of all organs.
format Text
id pubmed-1971364
institution National Center for Biotechnology Information
language English
publishDate 1990
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19713642009-09-10 An immunoradiometric assay of tumour-antigen 4 (TA-4): a comparison with conventional radioimmunoassay. Mino-Miyagawa, N. Kimura, Y. Hamamoto, K. Br J Cancer Research Article The serum level of tumour-antigen 4 (TA-4) was measured in 181 patients with squamous cell carcinoma (SCC) of various organs (71 lung, 24 uterus, 16 oesophagus, 64 head and neck and six skin), 34 patients with other types of lung cancer and 35 patients with benign diseases. To compare the results with those obtained by the conventional competitive radioimmunoassay (RIA) using a polyclonal antibody, a new immunoradiometric assay (IRMA) method was used which has recently been developed using two monoclonal antibodies raised to different epitopes of TA-4. Both methods provided essentially the same results: the serum TA-4 levels were high in patients with SCC of various organs when compared with those of healthy controls and patients with other types of lung cancer or benign diseases. However, the positive ratios assessed as the percentage of patients with elevated serum TA-4 levels were higher with the IRMA method than with the RIA method in SCC of all organs, as much as 2-3 times higher in SCC of the larynx, tongue and pharynx. In contrast, in patients with benign diseases or other types of lung cancer, there was no difference in the positive ratios between the two methods. This was largely due to the improvement in sensitivity and accuracy of assay with the new method, which resulted in a decrease in the normal value in healthy controls. It was concluded that with the new IRMA method using monoclonal antibodies, the diagnostic detectability of serum TA-4 is enhanced in SCC of all organs. Nature Publishing Group 1990-04 /pmc/articles/PMC1971364/ /pubmed/2331438 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Mino-Miyagawa, N.
Kimura, Y.
Hamamoto, K.
An immunoradiometric assay of tumour-antigen 4 (TA-4): a comparison with conventional radioimmunoassay.
title An immunoradiometric assay of tumour-antigen 4 (TA-4): a comparison with conventional radioimmunoassay.
title_full An immunoradiometric assay of tumour-antigen 4 (TA-4): a comparison with conventional radioimmunoassay.
title_fullStr An immunoradiometric assay of tumour-antigen 4 (TA-4): a comparison with conventional radioimmunoassay.
title_full_unstemmed An immunoradiometric assay of tumour-antigen 4 (TA-4): a comparison with conventional radioimmunoassay.
title_short An immunoradiometric assay of tumour-antigen 4 (TA-4): a comparison with conventional radioimmunoassay.
title_sort immunoradiometric assay of tumour-antigen 4 (ta-4): a comparison with conventional radioimmunoassay.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971364/
https://www.ncbi.nlm.nih.gov/pubmed/2331438
work_keys_str_mv AT minomiyagawan animmunoradiometricassayoftumourantigen4ta4acomparisonwithconventionalradioimmunoassay
AT kimuray animmunoradiometricassayoftumourantigen4ta4acomparisonwithconventionalradioimmunoassay
AT hamamotok animmunoradiometricassayoftumourantigen4ta4acomparisonwithconventionalradioimmunoassay
AT minomiyagawan immunoradiometricassayoftumourantigen4ta4acomparisonwithconventionalradioimmunoassay
AT kimuray immunoradiometricassayoftumourantigen4ta4acomparisonwithconventionalradioimmunoassay
AT hamamotok immunoradiometricassayoftumourantigen4ta4acomparisonwithconventionalradioimmunoassay